New drug combo shows promise for tough leukemia cases
NCT ID NCT02997761
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had come back or wasn't responding to treatment. The goal was to see how many patients achieved complete remission. The study is completed, and results will help determine if this approach is worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib and blinatumomab
What this could lead to
If it works, this combination could offer a new treatment option for patients whose leukemia has returned or stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. Side effects from the drugs can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States